- Home
- VRNA
VRNA
Verona Pharma plc
as 06-30-2025 4:00pm EST
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
| Founded: | 2005 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 8.3B | IPO Year: | 2017 |
| Target Price: | $105.38 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.15 - $99.01 | Next Earning Date: | 08-07-2025 |
| Revenue: | $118,535,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 891.79% | Revenue Growth (next year): | 78.94% |
Stock Insider Trading Activity of Verona Pharma plc (VRNA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Fisher Andrew | VRNA | General Counsel | Jun 16 '25 | Sell | $11.53 | 80,000 | $922,000.00 | 359,999 | |
| ZACCARDELLI DAVID | VRNA | President and CEO | Jun 11 '25 | Sell | $11.40 | 400,000 | $4,560,520.00 | 13,190,168 | |
| Hahn Mark W | VRNA | Chief Financial Officer | Jun 11 '25 | Sell | $11.40 | 400,000 | $4,560,360.00 | 12,278,992 | |
| ZACCARDELLI DAVID | VRNA | President and CEO | May 27 '25 | Sell | $9.39 | 400,000 | $3,734,578.84 | 13,190,168 | |
| Hahn Mark W | VRNA | Chief Financial Officer | May 27 '25 | Sell | $9.39 | 400,000 | $3,733,944.47 | 12,278,992 | |
| Sinha Vikas | VRNA | Director | May 20 '25 | Sell | $9.39 | 160,000 | $1,502,928.00 | 74,440 | |
| Fisher Andrew | VRNA | General Counsel | May 15 '25 | Sell | $8.57 | 80,000 | $685,600.00 | 359,999 | |
| ACKERMANN CHRISTINA | VRNA | Director | May 14 '25 | Sell | $8.44 | 40,000 | $337,600.00 | 41,880 | |
| Rickard Kathleen A. | VRNA | Chief Medical Officer | May 6 '25 | Sell | $8.82 | 114,984 | $1,014,342.85 | 2,546,472 | |
| ZACCARDELLI DAVID | VRNA | President and CEO | May 1 '25 | Sell | $9.00 | 587,008 | $5,311,279.00 | 13,190,168 |
Latest Verona Pharma plc News
VRNA Breaking Stock News: Dive into VRNA Ticker-Specific Updates for Smart Investing
TipRanks
7 days ago
Verona Pharma price target raised to $160 from $76 at Piper Sandler
Barchart
7 days ago
Up 515%, Watch This Biopharma Breakout
Insider Monkey
17 days ago
Jefferies Backs Verona Pharma plc (VRNA) After Strong Ohtuvayre Launch
Motley Fool
a month ago
Investing $15,000 Into Each of These 3 Stocks 5 Years Ago Would Have Created a Portfolio Worth $1 Million Today
Insider Monkey
a month ago
Jim Cramer Notes Verona Pharma plc (VRNA) “Loses a Lot of Money”
GlobeNewswire
a month ago
Verona Pharma Announces June 2025 Investor Conference Participation
Insider Monkey
2 months ago
Why Verona Pharma plc (VRNA) is Among the Best Performing Healthcare Stocks to Buy Now
Insider Monkey
2 months ago
What Makes Verona Pharma plc (VRNA) a Good Investment?
Compare VRNA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VRNA Verona Pharma plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.